Full Story

ACCCeXchange
Blog
Oncology Issues
Podcast

Welcome, !

Log out

Join/Renew
Learn
Attend
Connect
Advocate
News & Media
About

Share

In This Section

Join/Renew
Learn
Attend
Connect
Advocate
News & Media
About

Home / News & Media / Oncology Newsfeed / Full Story

FDA Approves Expanded Indication for Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
Immunogen Announces C-code for Mirvetuximab Soravtansine-gynx
FDA Grants Accelerated Approval to Retifanlimab-dlwr for MCC
FDA Approves Dabrafenib + trametinib for Pediatric Patients with LGG
FDA Approves Pegfilgrastim-cbqv
FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy
FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
FoundationOne®CDx and FoundationOne®Liquid CDx Receive Commercial Coverage
FDA Approves Dostarlimab-gxly for dMMR Endometrial Cancer
FDA Approves Sacituzumab Govitecan-hziy for HR-positive Breast Cancer
Biden Administration to End COVID-19 Public Health Emergency in May
FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer
FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC
FDA Approves Zanubrutinib for CLL or SLL
FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer
FDA Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Entrectinib
FDA Grants Accelerated Approval to Mosunetuzumab-axgb for R/R Follicular Lymphoma
FDA Approves FoundationOne Liquid CDx for Some Tyrosine Kinase Inhibitors in NSCLC
FDA Approves Additional Indication for Pemetrexed in Combination

1
2
3
4
5
6
7 (current)
8
9
10

1801 Research Boulevard, Suite 400, Rockville, MD 20850
Tel: 301.984.9496 Fax: 301.770.1949 Email Us

Corporate Members
Oncology State Societies
Privacy Policy

Copyright © 2024 Association of Cancer Care Centers. All Rights Reserved.